國立虎尾科技大學 |

Targeted Therapies for Lung Cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Targeted Therapies for Lung Cancer/ edited by Ravi Salgia.
other author:	Salgia, Ravi.
Description:	IX, 238 p. 19 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Cancer research. -
Online resource:	https://doi.org/10.1007/978-3-030-17832-1
ISBN:	9783030178321

Targeted Therapies for Lung Cancer
Targeted Therapies for Lung Cancer[electronic resource] /edited by Ravi Salgia. - 1st ed. 2019. - IX, 238 p. 19 illus. in color.online resource. - Current Cancer Research,2199-2584. - Current Cancer Research,.

1. EGFR -- 2. ALK -- 3. ROS1 -- 4. B-RAF -- 5. MET -- 6. HER2 -- 7. NTRK -- 8. SCLC -- 9. Complexities of the Lung Tumor Microenvironment -- 10. KRAS -- 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

ISBN: 9783030178321

Standard No.: 10.1007/978-3-030-17832-1doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Targeted Therapies for Lung Cancer
LDR:02777nam a22004095i 4500 001 1005585
003 DE-He213
005 20200702025733.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030178321 $9 978-3-030-17832-1
024 7 $a 10.1007/978-3-030-17832-1 $2 doi
035 $a 978-3-030-17832-1
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Targeted Therapies for Lung Cancer $h [electronic resource] / $c edited by Ravi Salgia.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a IX, 238 p. 19 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Current Cancer Research, $x 2199-2584
505 0 $a 1. EGFR -- 2. ALK -- 3. ROS1 -- 4. B-RAF -- 5. MET -- 6. HER2 -- 7. NTRK -- 8. SCLC -- 9. Complexities of the Lung Tumor Microenvironment -- 10. KRAS -- 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.
520 $a This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Salgia, Ravi. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1228593
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030178314
776 0 8 $i Printed edition: $z 9783030178338
776 0 8 $i Printed edition: $z 9783030178345
830 0 $a Current Cancer Research, $x 2199-2584 $3 1257028
856 4 0 $u https://doi.org/10.1007/978-3-030-17832-1
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)